Project Grant RF1AG098213
Award Date 8/1/26
Completion Date 7/31/29
Dollars Obligated $6.1M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded the University of Wisconsin System $568,615 on September 2, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the molecular mechanisms underlying synaptic deficiency in Down syndrome. The research project, titled "Molecular Mechanisms Underlying Synaptic Deficiency in Down Syndrome" (R01HD120347), will use isogenic trisomy 21 disorder-specific human...
- The National Institutes of Health Office of the Director awarded $2.693 million to the University of Wisconsin–Madison on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to establish an Alzheimer's disease biomarker clock in Down syndrome using positron emission tomography and plasma analytes. The research addresses the underrepresentation of individuals with Down syndrome in Alzheimer's disease therapeutic trials by characterizing biomarker progression in this...
- The National Institutes of Health Office of the Director awarded the Trustees of Boston University $763,348 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate how the HSA21-triplicated gene HMGN1 exacerbates neuropathological features in Down syndrome and Down syndrome-associated Alzheimer's disease. The research will examine HMGN1's dual mechanisms: its role as a nucleosome binding factor that facilitates chromatin accessibility and regulates genes...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
- The University of California, San Diego (UCSD) was awarded a $1,698,323 Project Grant from the National Institute on Aging (CFDA 93.866 Aging Research) to develop and validate a mouse model for Alzheimer's disease in Down syndrome (DS-AD). The goal is to create a genetically modified mouse that replicates key pathological features of DS-AD, including amyloid plaques, congophilic angiopathy, and neurofibrillary tangles. In the initial R61 phase, the researchers will demonstrate feasibility,...
- The National Institutes of Health Office of the Director awarded the University of New Mexico Health Sciences Center $419,375 on July 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate mechanisms of vascular dysfunction in Down syndrome. The research examines endothelial dysfunction and glycocalyx depletion in a mouse model of Down syndrome (TCMAC21 mice) to understand cardiovascular disease risk in the Down syndrome population. The study investigates how...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $980,965 to Montclair State University on August 13, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a project grant investigating spatial navigation as a domain-specific marker of cognitive decline in adults with Down syndrome. The research will recruit 40 adults with Down syndrome ages 35–50 to examine whether and how spatial navigation impairments relate to...
- The National Institute on Aging, within the Department of Health and Human Services, awarded The Medical College of Wisconsin, Inc. $429,000 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how overexpression of human chromosome 21 (HSA21) orthologs affects neurodegeneration during aging in Caenorhabditis elegans. The project addresses variability in dementia onset among individuals with Down syndrome, which results from trisomy 21. While approximately 75...
- The National Institute of Allergy and Infectious Diseases awarded $149,920 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, on January 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds a Project Grant (F31AI194862) titled "Deciphering Central Nervous System Autoimmunity in Down Syndrome." The research examines mechanisms linking interferon receptor triplication in Down syndrome to central...